Axsome Therapeutics to Report Fourth Quarter and Full Year 2020 Financial Results on March 1, 2021
16 févr. 2021 07h00 HE
|
Axsome Therapeutics, Inc.
Axsome to host conference call and webcast on Monday, March 1, 2021 at 8:00 AM Eastern Time NEW YORK, Feb. 16, 2021 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical...
Praxis Precision Medicines Receives Rare Pediatric Disease and Orphan Drug Designations for Severe Pediatric Epilepsy Programs
07 janv. 2021 08h00 HE
|
Praxis Precision Medicines, Inc
FDA grants RPD and ODD for PRAX-222 for treatment of SCN2A-DEE FDA grants RPD for PRAX-562 for treatment of SCN2A-DEE and SCN8A-DEE CAMBRIDGE, Mass., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Praxis...
Axsome Therapeutics Announces Positive Results from the COMET-SI Trial of AXS-05 in Patients with Major Depressive Disorder Who Have Suicidal Ideation
08 déc. 2020 06h00 HE
|
Axsome Therapeutics, Inc.
68% reduction in MADRS Suicidality Item score by Week 1, and 82% reduction by Week 4 Resolution of suicidal ideation achieved by 60% of patients by Week 1, and 78% by Week 4 Effects consistent with...
Axsome Therapeutics Announces Positive Results from the COMET-TRD Trial of AXS-05 in Patients with Treatment Resistant Depression
02 déc. 2020 06h00 HE
|
Axsome Therapeutics, Inc.
Rapid and substantial improvement in depressive symptoms achieved by 44% of patients at 2 weeks, 67% at 6 weeks (MADRS response), and sustained with long-term treatment Rapid and substantial...
Axsome Therapeutics Announces Positive Efficacy and Safety Results from Phase 3 COMET Long-Term Trial and COMET-AU Trial of AXS-05 in Major Depressive Disorder
01 déc. 2020 06h00 HE
|
Axsome Therapeutics, Inc.
Rapid and substantial improvement in depressive symptoms achieved by 40% of patients at 2 weeks, 73% at 6 weeks (MADRS response), and sustained over 12 months Rapid and substantial improvement in...
Axsome Therapeutics Reports Third Quarter 2020 Financial Results and Provides Business Update
05 nov. 2020 07h00 HE
|
Axsome Therapeutics, Inc.
COMET Phase 3 long-term safety trial of AXS-05 in MDD, and MOVEMENT Phase 3 long-term safety trial of AXS-07 in migraine completed NDA submissions for AXS-05 in depression expected in January 2021,...
Axsome Therapeutics and Veeva Systems Partner to Build Axsome’s Digital-Centric Commercialization™ Platform
04 nov. 2020 07h03 HE
|
Axsome Therapeutics, Inc.
Collaboration provides Axsome access to new digital technologies developed by Veeva NEW YORK and PLEASANTON, Calif., Nov. 04, 2020 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a...
Axsome Therapeutics to Present Data from the ADVANCE-1 Trial of AXS-05 in Alzheimer’s Disease Agitation at the 13th Clinical Trials on Alzheimer’s Disease (CTAD) Conference
03 nov. 2020 07h00 HE
|
Axsome Therapeutics, Inc.
NEW YORK, Nov. 03, 2020 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS)...
Axsome Therapeutics to Report Third Quarter 2020 Financial Results on November 5, 2020
28 oct. 2020 07h00 HE
|
Axsome Therapeutics, Inc.
Axsome to host conference call and webcast on Thursday, November 5, 2020 at 8:00 AM Eastern Time NEW YORK, Oct. 28, 2020 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a...
Axsome Therapeutics Announces $225 Million Term Loan Facility with Hercules Capital
29 sept. 2020 07h00 HE
|
Axsome Therapeutics, Inc.
Non-dilutive committed capital extends cash runway into at least 2024 Facility strengthens balance sheet through anticipated commercial launches of Axsome’s two lead CNS product candidates NEW YORK,...